Reaction Biology

Overview

Reaction Biology is a contract research organization founded in 2001, headquartered in Malvern, Pennsylvania, with additional facilities in Hershey, PA, Freiburg, Germany, and Heidelberg, Germany. The company specializes in preclinical drug discovery and development services, serving 2,000+ clients worldwide including pharmaceutical, biotech, and academic organizations.

Core Capabilities

Discovery Services:

• Integrated kinase discovery platform with kinase panel screening, kinase assays, cellular kinase assays, and custom kinase drug discovery
• Epigenetic assays including methyltransferase, demethylase, HDAC, and reader domain assays
• Target-specific assays for RAS, immune checkpoints, targeted protein degradation, PARP, phosphatases, proteases, ion channels, and GPCRs
• Biophysical assays (SPR, ITC, MST, thermal shift)
• Cell-based assays including 2D and 3D phenotypic screening, cell proliferation/viability, cell death, and migration assays
• Biomarker discovery with genetic, protein, and phenotypic biomarkers

Preclinical Services:

• In vivo pharmacology with xenograft models (subcutaneous, orthotopic, metastasis), hollow fiber models, and kinase activity models
• Immuno-oncology platform including CAR-T cell therapy, humanized xenografts, syngeneic models, and immunophenotyping
• In vitro safety screening and cardiac safety assessment
• GLP regulatory toxicology
• Biomarker analysis and immunohistochemistry

Clinical Support:

• Flow cytometry and multiplex immune assays
• Immunophenotyping services

Quality & Regulatory

Reaction Biology Europe operates under ISO 9001:2015 certification for recombinant protein products, biochemical, cellular, and immuno-oncology assay services, and in vivo testing. BSL2-equipped laboratories support studies across small molecules, antibodies, ADCs, oncolytic viruses, and bacteria-based agents. The company has supported hundreds of oncology therapies approved by the FDA and global regulatory agencies.